S100P and familial pancreatic carcinoma: In vivo data revealed that the S100P-derived inhibitor may have therapeutic potential against glioma and pancreatic cancer and may inhibit a variety of RAGE ligands, implying that it could be useful in additional RAGE-related diseases [3,85].